RemeGen Co., Ltd. (HKG:9995)

Market Cap	56.16B +111.3%
Revenue (ttm)	3.84B +76.8%
Net Income	1.47B
EPS	2.65
Shares Out	559.97M
PE Ratio	26.57
Forward PE	9.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,202,389
Open	73.75
Previous Close	72.40
Day's Range	70.25 - 75.10
52-Week Range	44.05 - 126.60
Beta	0.43
Analysts	Buy
Price Target	116.64 (+65.45%)
Earnings Date	Aug 17, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,048
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 17 analysts, the average rating for 9995 stock is "Buy." The 12-month stock price target is $116.64, which is an increase of 65.45% from the latest price.

Price Target

$116.64

(65.45% upside)

Analyst Consensus: Buy